116 related articles for article (PubMed ID: 12362973)
1. Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects.
Bartoszek A
Acta Biochim Pol; 2002; 49(2):323-31. PubMed ID: 12362973
[TBL] [Abstract][Full Text] [Related]
2. Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect.
Celik H; Arinç E
J Pharm Pharm Sci; 2008; 11(4):68-82. PubMed ID: 19183515
[TBL] [Abstract][Full Text] [Related]
3. Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.
Ramji S; Lee C; Inaba T; Patterson AV; Riddick DS
Cancer Res; 2003 Oct; 63(20):6914-9. PubMed ID: 14583491
[TBL] [Abstract][Full Text] [Related]
4. Activation of mitomycin C by NADPH:cytochrome P-450 reductase.
Bligh HF; Bartoszek A; Robson CN; Hickson ID; Kasper CB; Beggs JD; Wolf CR
Cancer Res; 1990 Dec; 50(24):7789-92. PubMed ID: 2123741
[TBL] [Abstract][Full Text] [Related]
5. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
6. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
7. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
[TBL] [Abstract][Full Text] [Related]
8. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Paine MJ; Korytowska A; Serwatka K; Piotrowska S; Wolf CR; Tarasiuk J
Cancer Lett; 2007 Jan; 245(1-2):252-62. PubMed ID: 16574318
[TBL] [Abstract][Full Text] [Related]
9. Production of superoxide radical in reductive metabolism of a synthetic food-coloring agent, indigocarmine, and related compounds.
Kohno Y; Kitamura S; Yamada T; Sugihara K; Ohta S
Life Sci; 2005 Jun; 77(6):601-14. PubMed ID: 15921992
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase.
Bartoszek A; Wolf CR
Biochem Pharmacol; 1992 Apr; 43(7):1449-57. PubMed ID: 1567469
[TBL] [Abstract][Full Text] [Related]
11. The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro.
Graham MA; Newell DR; Butler J; Hoey B; Patterson LH
Biochem Pharmacol; 1987 Oct; 36(20):3345-51. PubMed ID: 2823819
[TBL] [Abstract][Full Text] [Related]
12. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
Lu H; Waxman DJ
Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
[TBL] [Abstract][Full Text] [Related]
15. The structural basis for anthracycline antibiotic stimulation of oxygen consumption by HL-60 cells and mitochondria.
Burke TG; Pritsos CA; Sartorelli AC; Tritton TR
Cancer Biochem Biophys; 1987 Sep; 9(3):245-55. PubMed ID: 3124953
[TBL] [Abstract][Full Text] [Related]
16. Oxidative DNA damage induced by carcinogenic dinitropyrenes in the presence of P450 reductase.
Murata M; Ohnishi S; Seike K; Fukuhara K; Miyata N; Kawanishi S
Chem Res Toxicol; 2004 Dec; 17(12):1750-6. PubMed ID: 15606153
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of a doxorubicin-inhibited NADH-quinone (NADH-ferricyanide) reductase from rat liver plasma membranes.
Kim C; Crane FL; Faulk WP; Morré DJ
J Biol Chem; 2002 May; 277(19):16441-7. PubMed ID: 11875069
[TBL] [Abstract][Full Text] [Related]
18. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
Shimada T; Mernaugh RL; Guengerich FP
Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
[TBL] [Abstract][Full Text] [Related]
19. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
20. Interactions of anticancer quinone drugs, aclacinomycin A, adriamycin, carbazilquinone, and mitomycin C, with NADPH-cytochrome P-450 reductase, xanthine oxidase and oxygen.
Komiyama T; Kikuchi T; Sugiura Y
J Pharmacobiodyn; 1986 Aug; 9(8):651-64. PubMed ID: 3023600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
